Articles
Regulatory Analysis
In-depth, citation-backed writing on regulatory analysis. · 2 articles in Regulatory Analysis
Which of the Seven Peptides Reviewed by the FDA's July 2026 Advisory Panel Have Sufficient Human Safety and Efficacy Data to Justify Compounding?
Of the seven peptides evaluated by the FDA's Compounding Advisory Committee in July 2026, only Semax carries a meaningful human clinical dataset — a Russian regulatory approval backed by published controlled trials. MOTS-c and Epitalon have limited observational human data. BPC-157, TB-500, KPV, and Emideltide lack adequate human safety or efficacy evidence by the FDA's 503A evidentiary standard.
What Does the FDA Panel's July 2026 Compounding Recommendation Mean for BPC-157, TB-500, and KPV When Human Efficacy Data Are Absent?
The FDA advisory panel's July 2026 vote recommended against adding BPC-157, TB-500, and KPV to the 503A bulk drug substance list, citing the absence of adequate and well-controlled human trials for all three compounds. The recommendation is non-binding but signals that compounding pharmacies cannot rely on these substances meeting the agency's clinical-need standard.